Biogen Clinical Trial Pipeline — 49 Active Studies

Biogen pipeline at a glance (March 2026)

About the Biogen clinical program

Biogen is the world's leading company in neuroscience drug development, with deep pipelines across Alzheimer's disease, multiple sclerosis, rare neurological conditions, and neuromuscular disease. Leqembi (lecanemab), developed with Eisai, is the first anti-amyloid antibody to receive full FDA approval for early Alzheimer's — validated by the CLARITY AD trial. Their multiple sclerosis portfolio (Tysabri, Tecfidera/Vumerity, natalizumab biosimilars) remains a major franchise supporting pipeline investment. In neuromuscular disease, Spinraza (nusinersen) pioneered SMA treatment. Biogen's rare neurology pipeline includes Skyclarys (omaveloxolone) for Friedreich ataxia — one of the first approved treatments for this orphan disease — and a growing number of gene therapy and antisense oligonucleotide programs targeting devastating neurological conditions.

Key therapeutic areas

• Alzheimer's disease / neurodegeneration
• Multiple sclerosis
• Neuromuscular disease (SMA, ALS)
• Rare neurological disorders (Friedreich ataxia)
• Stroke / neuroinflammation

Key pipeline programs

• Leqembi (lecanemab) — anti-amyloid antibody, early Alzheimer's
• Skyclarys (omaveloxolone) — Nrf2 activator, Friedreich ataxia
• Tysabri (natalizumab) — anti-α4 integrin, MS
• Spinraza (nusinersen) — ASO, spinal muscular atrophy
• BIIB059 — BDCA2, systemic lupus erythematosus
• Tofersen — SOD1-ALS antisense oligonucleotide

Top Biogen trial indications

Condition / Indication	Trials
["Muscular Atrophy, Spinal"]	5
["Healthy Volunteer"]	4
["Friedreich Ataxia"]	3
["Alzheimer's Disease"]	3
["Relapsing Forms of Multiple Sclerosis"]	2
["Solid Tumor"]	2
["Antibody-mediated Rejection"]	2
["Lupus Erythematosus, Systemic"]	2

Why monitor Biogen's clinical trial activity

Biogen's Alzheimer's disease pipeline — Leqembi (lecanemab) combinations, next-generation anti-tau programs, and disease biomarker trials — generates significant new registrations as the field validates anti-amyloid therapy. Their ALS program, including tofersen (Qalsody) for SOD1-ALS, is watched by neurology-focused BD and rare disease teams.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Biogen's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Biogen trials

• Sponsor normalization: Biogen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What is Biogen's focus in Alzheimer's disease clinical trials?

Biogen's Alzheimer's activities center on Leqembi (lecanemab) in earlier populations — pre-symptomatic and prevention trials — and combination approaches targeting multiple pathways. They also maintain research into tau-targeting therapies and programs in downstream neuroinflammatory mechanisms. The field is evolving rapidly and Biogen is registering new studies as the anti-amyloid evidence base expands.

How many Biogen trials are currently recruiting?

Based on current ClinicalTrials.gov data, 19 Biogen-sponsored trials are actively recruiting patients across neuroscience, rare disease, and other therapeutic areas.

Does DataLookout track Biogen's rare neurology programs?

Yes. ClinicalTrials.gov includes Biogen trials across all indications, including rare neurological programs like Skyclarys (Friedreich ataxia), tofersen (SOD1-ALS), and next-generation gene therapy and ASO programs. Monitor Biogen as a sponsor to receive alerts across their full pipeline.